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Neutralization of hyperalgesia induced by Bothrops jararaca and B.
asper venoms was studied in rats using bothropic antivenom produced
at Instituto Butantan (AVIB, 1 ml neutralizes 5 mg B. jararaca venom)
and polyvalent antivenom produced at Instituto Clodomiro Picado
(AVCP, 1 ml neutralizes 2.5 mg B. aspar venom). The intraplantar
injection of B. jararaca and B. asper venoms caused hyperalgesia,
which peaked 1 and 2 h after injection, respectively. Both venoms also
induced edema with a similar time course. When neutralization assays
involving the independent injection of venom and antivenom were
performed, the hyperalgesia induced by B. jararaca venom was
neutralized only when bothropic antivenom was administered iv 15
min before venom injection, whereas edema was neutralized when
antivenom was injected 15 min or immediately before venom injec-
tion. On the other hand, polyvalent antivenom did not interfere with
hyperalgesia or edema induced by B. asper venom, even when admin-
istered prior to envenomation. The lack of neutralization of hyperalge-
sia and edema induced by B. asper venom is not attributable to the
absence of neutralizing antibodies in the antivenom, since neutraliza-
tion was achieved in assays involving preincubation of venom and
antivenom. Cross-neutralization of AVCP or AVIB against B. jara-
raca and B. asper venoms, respectively, was also evaluated. Only
bothropic antivenom partially neutralized hyperalgesia induced by B.
asper venom in preincubation experiments. The present data suggest
that hyperalgesia and edema induced by Bothrops venoms are poorly
neutralized by commercial antivenoms even when antibodies are
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Introduction
Antivenoms of equine or ovine origin
constitute the only effective treatment of
snakebite envenomation (1). The use of these
products has greatly contributed to the re-
duction of mortality owing to their effective-
ness in the neutralization of life-threatening,
systemically acting toxins present in snake
venoms (2-4). Randomized controlled clini-
cal trials have demonstrated that antivenoms
are highly effective in halting systemic bleed-
ing, coagulopathies and other cardiovascu-
lar disturbances due to envenomations by
snakes of the family Viperidae in Latin
America (3,5-7).
In contrast, the effectiveness of antiven-
oms in neutralizing local effects induced by
pit viper venoms is doubtful. Experimental
studies have suggested that there is signifi-
cant, albeit partial, neutralization of hemor-
rhage, edema, dermonecrosis and myone-
crosis only when antivenom is administered
rapidly after envenomation (8-10), even when
using antibody fragments F(ab’)2 and Fab
which have a larger volume of distribution
and reach the interstitial fluid at a faster rate
(11,12). Clinical observations also indicate
that local tissue damage is only partially
halted by antivenoms (2,3,13).
Most experimental studies concerning
neutralization of local effects have dealt with
myonecrosis, hemorrhage and edema (for a
review, see Ref. 10), but little attention has
been paid to the study of pain, which is a
clinically relevant consequence of snake-
bites and occurs in the vast majority of pa-
tients bitten by Bothrops sp (3,13,14). Phar-
macological studies carried out with B. jara-
raca and B. asper venoms have indicated
that the hyperalgesic effect is based on the
action of a number of inflammatory media-
tors such as leukotrienes, prostaglandins and
platelet-activating factor, in the case of B.
jararaca (15), and bradykinin and leukotri-
enes in the case of B. asper (16). However,
there have been no investigations on the
ability of antivenoms to neutralize this ef-
fect. The present study was designed to as-
sess the neutralization of the hyperalgesic
effect induced by B. asper and B. jararaca
venoms by polyspecific antivenoms used
clinically in Central and South America. For
comparative purposes, the neutralizing abil-
ity of antivenoms against edema induced by
both venoms was also investigated.
Material and Methods
Animals
Male Wistar rats weighing 170 to 190 g
were maintained under controlled tempera-
tures (22-25ºC) and on a 12-h light/dark
cycle, with free access to food and water.
Venoms
Lyophilized crude venom of B. jararaca
(BjV) was supplied by Laboratório de Her-
petologia, Instituto Butantan, São Paulo, SP,
Brazil, and lyophilized crude venom of B.
asper (BaV) was supplied by Instituto
Clodomiro Picado, Costa Rica. Both venoms
were kept at -20ºC and dissolved in sterile
0.15 M NaCl (saline solution) at the time of
use.
Antivenoms
Bothropic antivenom of Instituto Butan-
tan, batches 9710158 and 9805055 (AVIB -
anti-B. jararaca, anti-B. jararacussu, anti-
B. moojeni, anti-B. neuwiedii and anti-B.
alternatus), and polyvalent antivenom of
Instituto Clodomiro Picado, batch 2811096
(AVCP - anti-B. asper, anti-C.d. durissus
and anti-L.m. stenophrys) were used in this
study. Antivenoms were stored at 4ºC. The
immunization protocols and adjuvants used
have been previously described by Raw et
al. (17) and Angulo et al. (18). Both antiven-
oms were liquid preparations used before
their expiration date.
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Evaluation of hyperalgesia
The animals were injected with 5 µg of
BjV or 15 µg of BaV dissolved in 100 µl
sterile saline solution into the subplantar
surface of one hind paw. Control animals
were injected with the same volume of ster-
ile saline. The contralateral paw was not
injected. The pain threshold was measured
at 1 and 4 h or 2 and 4 h after BjV and BaV
injection, respectively, or after saline injec-
tion using an Ugo-Basile pressure appara-
tus, essentially as described by Randall and
Selitto (19). Briefly, a force (in g) of increas-
ing magnitude was applied to the paw. The
force needed to induce the rat to withdraw its
paw was recorded and represented the pain
threshold.
Evaluation of edema formation
Rats received an injection of 5 µg BjV or
15 µg BaV dissolved in 100 µl sterile saline
solution (0.15 M NaCl) into the subplantar
surface of one hind paw. An equal volume of
saline was injected into the contralateral paw
(control). The volume increase (edema) of
the paws was measured plethysmographi-
cally at 1 and 4 h or 2 and 4 h after BjV and
BaV injection, respectively, according to the
method of Van Arman et al. (20). The differ-
ence between the values obtained for both
paws expressed as percent increase in paw
volume was used as a measure of edema.
Neutralization studies
Two kinds of experiments were per-
formed: 1) injection of antivenom at differ-
ent times before or after venom administra-
tion and 2) in vitro incubation of venom and
antivenom before injection.
Assays with independent injection of
venom and antivenom. Antivenoms (0.5 ml)
were administered iv 15 min or immediately
before or 15 min after intraplantar injection
of the venoms. Hyperalgesia and edema
measurements were carried out as described
above.
Assays with preincubation of venom and
antivenom. A constant amount of venom
was incubated with several dilutions of anti-
venom at the following antivenom/venom ra-
tios: 1, 0.5, 0.25, 0.125 ml antivenom/mg
venom. After incubation at 37ºC for 30 min,
100 µl of each mixture containing the appro-
priate amounts of venoms (5 µg BjV or 15 µg
BaV) were injected by the intraplantar route,
and hyperalgesia and edema were determined
as described above.
Cross-neutralization studies. Cross-
neutralization experiments were performed
in order to determine if AVIB and AVCP
antivenoms are able to neutralize the hyper-
algesic and edematogenic effects induced
by B. asper and B. jararaca venoms, respec-
tively. The neutralization studies were car-
ried out as described above for assays with
independent injection of venom and anti-
venom or assays with preincubation of ven-
om and antivenom. In preincubation assays,
the antivenom/venom ratios used were 2 ml
antivenom/mg venom for AVCP/BjV and
1 ml antivenom/mg venom for AVIB/BaV.
The antivenoms did not alter, per se, the
pain threshold of the animals, nor did they
induce an edematogenic response (data not
shown).
Statistical analysis
Data were analyzed statistically by anal-
ysis of variance and sequential differences
among means were determined by Tukey
contrast analysis, with the level of signifi-
cance set at P<0.05 (21).
Results
Neutralization of hyperalgesia and edema
induced by Bothrops jararaca venom
The intraplantar injection of BjV (5 µg/
paw) into the rat hind paw caused a signifi-
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cant decrease in pain threshold (hyperalge-
sia) and an increase in paw volume. The
peak of the hyperalgesic and edematogenic
responses occurred 1 h after venom injec-
tion. After this time both phenomena started
to decrease (Figure 1) and completely disap-
peared at 24 h (data not shown). When venom
and antivenom were injected separately, neu-
tralization of BjV-induced hyperalgesia was
observed only when AVIB was adminis-
tered 15 min before venom injection (Figure
1A). Administration of AVIB 15 min or
immediately before BjV induced a marked
reduction of edema, although this effect was
not completely neutralized (Figure 1B).
In experiments with incubation of venom
and antivenom prior to injection, antivenom
was effective in neutralizing the hyperalge-
sia and edema induced by BjV (Figure 2).
Full protection against hyperalgesia was
achieved at antivenom/venom ratios of 5 µl/
5 µg (1 ml/mg) and 0.625 µl/5 µg (0.125 ml/
mg) (Figure 2A), whereas edema was sig-
nificantly reduced but not abolished at the
same antivenom/venom ratios (Figure 2B).
Neutralization of hyperalgesia and edema
induced by Bothrops asper venom
The intraplantar injection of BaV (15 µg/
paw) induced hyperalgesia and edema which
peaked 2 h after venom injection, decreasing
thereafter (Figure 3). AVCP administered
15 min or immediately before or 15 min after
B. asper venom injection did not modify the
hyperalgesia or edema induced by the venom
(Figure 3). In experiments involving prein-
cubation, AVCP neutralized hyperalgesia at
the antivenom/venom ratio of 3.75 µl/15 µg
(0.250 ml/mg), whereas a partial neutraliza-
tion of edema was observed at the anti-
venom/venom ratio of 15 µl/15 µg (1 ml/mg)
(Figure 4).
Cross-neutralization studies
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Figure 2. Neutralization of the
hyperalgesia and edema in-
duced by Bothrops jararaca
venom by bothropic antivenom
in assays in which venom and
antivenom were incubated to-
gether before injection into the
rat paw. The same amount of
venom (V, 5 µg/paw), was incu-
bated with various dilutions of
antivenom (AV) or with saline (S,
control) for 30 min at 37ºC. Then,
100 µl of the mixtures contain-
ing 5 µg of venom were injected
by the intraplantar route. The
decrease in threshold response
(A) and increase in paw volume
(B) were determined in rat hind
paws before and 1 and 4 h after
injection of the venom. Sensitiv-
ity to pain was measured as the
threshold response to pressure
and is reported in grams. Edema
is reported as percent increase
in relation to the initial volume of
the paw. Each point indicates
the mean ± SEM for 6 animals.
*P<0.05 compared to the S + V
group (ANOVA followed by
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Figure 1. Neutralization of the hy-
peralgesia and edema activity of
Bothrops jararaca venom by
bothropic antivenom in assays in
which venom and antivenom
were injected separately. Anti-
venom (AV, 0.5 ml, 15 mg pro-
tein) or saline control (S, 0.5 ml)
was injected iv 15 min before,
immediately before or 15 min af-
ter intraplantar injection of the
venom (V, 5 µg/paw). The de-
crease in threshold response (A)
and increase in paw volume (B)
were determined in rat hind
paws before and 1 and 4 h after
injection of the venom. Sensitivi-
ty to pain was measured as the
threshold response to pressure
and is reported in grams. Edema
is reported as percent increase
in relation to the initial volume of
the paw. V + S (squares); V + AV
15 min before (filled circles); V +
AV immediately before (open
circles) or V + AV 15 min after
(triangles). Each point indicates
the mean ± SEM for 6 animals. *P<0.05 compared to the S + V group (ANOVA followed by
Tukey test). Note that the abscissa scale is not linear.
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BaV and BjV, respectively, did not modify
the hyperalgesia or edema induced by both
venoms (data not shown). In experiments
involving incubation of venom and anti-
venom prior to injection, AVIB partially
neutralized the hyperalgesia and edema in-
duced by BaV (Figure 5A,B). On the other
hand, AVCP did not modify either effect
induced by B. jararaca venom. One hour
after intraplantar injection of neutralized
venom, the pain threshold was 47 ± 1.2 g and
the increase in paw volume was 64 ± 8%.
The data for the control (non-neutralized
venom) group were 53 ± 2 g for pain thresh-
old and 47 ± 8% for paw volume increase.
Discussion
Bothropic and polyvalent antivenoms
constitute the major therapeutic resource in
snakebite envenomations in Brazil and Cen-
tral America, respectively (3,22). Clinical
investigations have demonstrated the effi-
cacy of these products on the neutralization
of life-threatening systemic effects associ-
ated with these envenomations (3,5,14).
However, experimental and clinical evidence
indicates that local effects in Bothrops sp
envenomations are poorly neutralized by
these and other antivenoms (3,8,10,13). The
present results further demonstrate the com-
plete ineffectiveness of these antivenoms in
neutralizing the local edema and hyperalge-
sia induced by B. asper and B. jararaca
venoms when antivenoms are administered
to rats after envenomation.
The ability of antivenoms to neutralize
hyperalgesia has not been previously ad-
dressed in experimental studies, despite the
fact that pain is a common manifestation of
Bothrops sp envenomations (3,13,23). We
selected venom doses which caused an in-
crease in the sensitivity to pain (hyperalge-
sia) and local edema, without inducing mac-
roscopically evident hemorrhage or tissue
damage. Such doses have been validated
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A
Figure 3. Neutralization of the
hyperalgesia and edema activity
of Bothrops asper venom by
polyvalent antivenom in assays
in which venom and antivenom
were injected separately. Anti-
venom (AV, 0.5 ml, 22 mg pro-
tein) or saline (S, control group)
was injected iv 15 min before,
immediately before or 15 min
after intraplantar injection of the
venom (V, 15 µg/paw). The de-
crease in threshold response (A)
and increase in paw volume (B)
were determined in rat hind
paws before and 2 and 4 h after
injection of the venom. Sensitiv-
ity to pain was measured as the
threshold response to pressure
and is reported in grams. Edema
is reported as percent increase
in relation to the initial volume of
the paw. V + S (squares); V + AV
15 min before (circles); V + AV
immediately before (triangles) or
V + AV 15 min after (inverted
triangles). Each point indicates
the mean ± SEM for 6 animals.
B
Figure 4. Neutralization of the
hyperalgesia and edema in-
duced by Bothrops asper venom
by polyvalent antivenom in as-
says in which venom and anti-
venom were incubated together
before injection into rats. A fixed
amount of venom (V) was incu-
bated with various dilutions of
antivenom (AV) or with saline (S,
control) for 30 min at 37ºC. Then,
100 µl of the mixtures contain-
ing 15 µg of venom were in-
jected by the intraplantar route.
The decrease in threshold re-
sponse (A) and increase in paw
volume (B) were determined in
rat hind paws before and 2 and 4
h after injection of the venom.
Sensitivity to pain was meas-
ured as the threshold response
to pressure and is reported in
grams. Edema is reported as
percent increase in relation to
the initial volume of the paw.
Each point indicates the mean ±
SEM for 6 animals. *P<0.05
compared to the S + V group
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similar situation occurs regarding the neu-
tralization of hemorrhage and myonecrosis
induced by B. asper venom (8-10). It has
been suggested that the observed poor neu-
tralization is based on the fact that hyperal-
gesia and edema develop at an extremely
rapid rate after venom injection, associated
with the release of endogenous mediators
involved in these pharmacological effects
(15,16,25,26). Thus, by the time antivenom
antibodies reach the affected tissues, it is
likely that the cascade of inflammatory events
associated with hyperalgesia and edema has
already started. Moreover, since antivenoms
are administered intravenously, the amount
of antibodies diffusing to the affected tissues
is probably insufficient and delayed. Thus,
an evident mismatch occurs between the
pharmacokinetics and pharmacodynamics of
venoms and antivenoms in this experimental
model and, very likely, in the clinical situa-
tion as well.
The present study also addressed the is-
sue of cross-neutralization of these effects
by antivenoms. Previous investigations have
documented cross-neutralization between
bothropic and polyvalent antivenoms when
assayed against a variety of venoms from
Central and South America (27-30). The
present results demonstrate that bothropic
antivenom partially neutralizes B. asper
venom, whereas polyvalent antivenom is
largely ineffective in the neutralization of
edema and hyperalgesia induced by B. jara-
raca venom. It is likely that components
immunologically related to hyperalgesic and
edematogenic toxins in B. asper venom are
present in one or more of the venoms in-
cluded in the antigenic mixture used to pro-
duce bothropic antivenom in Brazil.
The present study reports the first exper-
imental evidence showing that hyperalgesia
induced by Bothrops sp venoms is not neu-
tralized when antivenoms are administered
after envenomation. In view of the clinical
relevance of pain in Bothrops sp envenoma-
tions, it is necessary to gain further under-
Figure 5. Neutralizing activity of
bothropic antivenom (AVIB)
against Bothrops asper venom
in assays involving incubation of
the venom and the antivenom
together before injection. A fixed
amount of venom was incubated
with dilutions of antivenom or
with saline (S, control) for 30 min
at 37ºC. Then, 100 µl of the mix-
ture containing 15 µg of B. asper
venom (BaV) was injected by the
intraplantar route. The decrease
in threshold response (A) and in-
crease in paw volume (B) were
measured in rat hind paws be-
fore and 2 and 4 h after the injec-
tion of BaV. Sensitivity to pain
was measured as the threshold
response to pressure and is re-
ported in grams. Edema is re-
ported as percent increase in re-
lation to the initial volume of the
paw. Each point indicates the
mean ± SEM for 6 animals.
*P<0.05 compared to the BaV +
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Bothropic antivenom produced against
B. jararaca at Instituto Butantan was inef-
fective in neutralizing edema or hyperalge-
sia when administered after envenomation.
Only when antivenom was injected before
venom was neutralization achieved. In the
case of B. asper venom, polyvalent anti-
venom produced in Costa Rica was ineffec-
tive in neutralizing edema or hyperalgesia
when administered either before or after en-
venomation, in agreement with prior obser-
vations in mice (8,10). Moreover, Rucavado
and Lomonte (24) demonstrated that the pres-
ence of antibodies in the circulation before
injection of B. asper venom in mice reduces,
but does not abolish, local tissue damage.
Such poor neutralizing efficacy cannot
be explained on the basis of lack of neutral-
izing antibodies in these antivenoms, since
both hyperalgesic and edematogenic re-
sponses were abolished if venom and anti-
venoms were incubated prior to injection. A
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standing of the pharmacological mechan-
isms involved in this effect, as well as of the
characteristics of the hyperalgesic compo-
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